Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase

Genes and Development

Volumn 28, Issue 13, 2014, Pages 1429-1444

  Zheng, Xingnan ^a   Zhai, Bo ^b   Koivunen, Peppi ^c   Shin, Sandra J ^d   Lu, Gang ^b   Liu, Jiayun ^b   Geisen, Christoph ^b   Chakraborty, Abhishek A ^b   Moslehi, Javid J ^b   Smalley, David M ^a   Wei, Xin ^a   Chen, Xian ^a   Chen, Zhengming ^d   Beres, Justine M ^a   Zhang, Jing ^a   Tsao, Jen Lan ^e   Brenner, Mitchell C ^e   Zhang, Yuqing ^d   Fan, Cheng ^a   DePinho, Ronald A ^f   Paik, Jihye ^d   Gygi, Steven P ^b   Kaelin Jr , William G ^b,g   Zhang, Qing ^a   more..

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF OULU   (Finland)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e FIBROGEN INC   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Breast cancer; Cyclin D1; EglN2; FOXO3a; Prolyl hydroxylation; USP9x

Indexed keywords

CYCLIN D1; DEUBIQUITINASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLINE; PROLYL HYDROXYLASE EGLN2; PROTEASOME; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG; USP9X PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE REPRESSION; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY;

BREAST CANCER; CYCLIN D1; EGLN2; FOXO3A; PROLYL HYDROXYLATION; USP9X;

ANIMALS; CELL LINE; CELLS, CULTURED; CYCLIN D1; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HYDROXYLATION; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; MCF-7 CELLS; MICE; PROTEIN BINDING; PROTEIN STABILITY; UBIQUITIN THIOLESTERASE;

EID: 84903769379     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.242131.114     Document Type: Article

References (74)

1. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ, Gleadle JM. 2004. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 279: 38458-38465.
2. Aragones J, Schneider M, Van Geyte K, Fraisl P, Dresselaers T, Mazzone M, Dirkx R, Zacchigna S, Lemieux H, Jeoung NH, et al. 2008. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet 40: 170-180.
3. Bakker WJ, Harris IS, Mak TW. 2007. FOXO3a is activated in response to hypoxic stress and inhibits HIF1-induced apoptosis via regulation of CITED2. Mol Cell 28: 941-953.
4. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. 2003. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1a in normoxia. EMBO J 22: 4082-4090.
5. Beuck S, Schanzer W, Thevis M. 2012. Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis. Drug Test Anal 4: 830-845.
6. -/- mice. Mol Cell Biol 28: 3386-3400.
7. Bruick RK, McKnight SL. 2001. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294: 1337-1340.
8. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. 1999. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868.
9. Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME. 2001. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol 21: 952-965.
10. Brunet A, Kanai F, Stehn J, Xu J, Sarbassova D, Frangioni JV, Dalal SN, DeCaprio JA, Greenberg ME, Yaffe MB. 2002. 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J Cell Biol 156: 817-828.
11. Cancer Genome Atlas Research Network. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
12. Cummins EP, Berra E, Comerford KM, Ginouves A, Fitzgerald KT, Seeballuck F, Godson C, Nielsen JE, Moynagh P, Pouyssegur J, et al. 2006. Prolyl hydroxylase-1 negatively regulates IkB kinase-b, giving insight into hypoxia-induced NFkB activity. Proc Natl Acad Sci 103: 18154-18159.
13. Dupont S, Mamidi A, Cordenonsi M, Montagner M, Zacchigna L, Adorno M, Martello G, Stinchfield MJ, Soligo S, Morsut L, et al. 2009. FAM/USP9x, a deubiquitinating enzyme essential for TGFb signaling, controls Smad4 monoubiquitination. Cell 136: 123-135.
14. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, et al. 2001. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54.
15. Essafi A, Fernandez de Mattos S, Hassen YA, Soeiro I, Mufti GJ, Thomas NS, Medema RH, Lam EW. 2005. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene 24: 2317-2329.
16. Feng T, Yamamoto A, Wilkins SE, Sokolova E, Yates LA, Munzel M, Singh P, Hopkinson RJ, Fischer R, Cockman ME, et al. 2014. Optimal translational termination requires C4 lysyl hydroxylation of eRF1. Mol Cell 53: 645-654.
17. Ferber EC, Peck B, Delpuech O, Bell GP, East P, Schulze A. 2012. FOXO3a regulates reactive oxygen metabolism by inhibiting mitochondrial gene expression. Cell Death Differ 19: 968-979.
18. Fraisl P, Aragones J, Carmeliet P. 2009. Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov 8: 139-152.
19. Greer EL, Brunet A. 2005. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24: 7410-7425.
20. Guo S, Sonenshein GE. 2004. Forkhead box transcription factor FOXO3a regulates estrogen receptor a expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol 24: 8681-8690.
21. Habashy HO, Rakha EA, Aleskandarany M, Ahmed MA, Green AR, Ellis IO, Powe DG. 2011. FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer. Breast Cancer Res Treat 129: 11-21.
22. Hirsila M, Koivunen P, Gunzler V, Kivirikko KI, Myllyharju J. 2003. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem 278: 30772-30780.
23. Hirsila M, Koivunen P, Xu L, Seeley T, Kivirikko KI, Myllyharju J. 2005. Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway. FASEB J 19: 1308-1310.
24. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, et al. 2004. IkB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117: 225-237.
25. Huang H, Tindall DJ. 2007. Dynamic FoxO transcription factors. J Cell Sci 120: 2479-2487.
26. 2 sensing. Science 292: 464-468.
27. Ivan M, Haberberger T, Gervasi DC, Michelson KS, Gunzler V, Kondo K, Yang H, Sorokina I, Conaway RC, Conaway JW, et al. 2002. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci 99: 13459-13464.
28. 2-regulated prolyl hydroxylation. Science 292: 468-472.
29. Jensen KS, Binderup T, Jensen KT, Therkelsen I, Borup R, Nilsson E, Multhaupt H, Bouchard C, Quistorff B, Kjaer A, et al. 2011. FoxO3A promotes metabolic adaptation to hypoxia by antagonizing Myc function. EMBO J 30: 4554-4570.
30. Jiang Y, Zou L, Lu WQ, Zhang Y, Shen AG. 2013. Foxo3a expression is a prognostic marker in breast cancer. PLoS ONE 8: e70746.
31. Kaelin WG. 2005. Proline hydroxylation and gene expression. Annu Rev Biochem 74: 115-128.
32. Kaelin WG Jr, Ratcliffe PJ. 2008. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30: 393-402.
33. Kim WY, Safran M, Buckley MR, Ebert BL, Glickman J, Bosenberg M, Regan M, Kaelin WG Jr. 2006. Failure to prolyl hydroxylate hypoxia-inducible factor a phenocopies VHL inactivation in vivo. EMBO J 25: 4650-4662.
34. Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, Losman JA, Joensuu P, Bergmann U, Gross S, et al. 2012. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483: 484-488.
35. Kwon HS, Huang B, Unterman TG, Harris RA. 2004. Protein kinase B-a inhibits human pyruvate dehydrogenase kinase-4 gene induction by dexamethasone through inactivation of FOXO transcription factors. Diabetes 53: 899-910.
36. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin WG Jr, et al. 2005. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8: 155-167.
37. Lin C, Wu Z, Lin X, Yu C, Shi T, Zeng Y, Wang X, Li J, Song L. 2011. Knockdown of FLOT1 impairs cell proliferation and tumorigenicity in breast cancer through upregulation of FOXO3a. Clin Cancer Res 17: 3089-3099.
38. Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, Cole RN, Pandey A, Semenza GL. 2011. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145: 732-744.
39. Mabon ME, Scott BA, Crowder CM. 2009. Divergent mechanisms controlling hypoxic sensitivity and lifespan by the DAF-2/insulin/IGF-receptor pathway. PLoS ONE 4: e7937.
40. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. 2001. Independent function of two destruction domains in hypoxia-inducible factor-a chains activated by prolyl hydroxylation. EMBO J 20: 5197-5206.
41. Minamishima YA, Moslehi J, Bardeesy N, Cullen D, Bronson RT, Kaelin WG Jr. 2008. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 111: 3236-3244.
42. Minamishima YA, Moslehi J, Padera RF, Bronson RT, Liao R, Kaelin WG Jr. 2009. A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo. Mol Cell Biol 29: 5729-5741.
43. Miyamoto K, Araki KY, Naka K, Arai F, Takubo K, Yamazaki S, Matsuoka S, Miyamoto T, Ito K, Ohmura M, et al. 2007. Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 1: 101-112.
44. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, Piqani B, Eisenhaure TM, Luo B, Grenier JK, et al. 2006. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124: 1283-1298.
45. Moslehi J, Minamishima YA, Shi J, Neuberg D, Charytan DM, Padera RF, Signoretti S, Liao R, Kaelin WG Jr. 2010. Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Circulation 122: 1004-1016.
46. Mouchantaf R, Azakir BA, McPherson PS, Millard SM, Wood SA, Angers A. 2006. The ubiquitin ligase itch is auto-ubiquitylated in vivo and in vitro but is protected from degradation by interacting with the deubiquitylating enzyme FAM/USP9X. J Biol Chem 281: 38738-38747.
47. Nwogu JI, Geenen D, Bean M, Brenner MC, Huang X, Buttrick PM. 2001. Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction. Circulation 104: 2216-2221.
48. Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, Miao L, Tothova Z, Horner JW, Carrasco DR, et al. 2007. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128: 309-323.
49. Perez-Mancera PA, Rust AG, van der Weyden L, Kristiansen G, Li A, Sarver AL, Silverstein KA, Grutzmann R, Aust D, Rummele P, et al. 2012. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 486: 266-270.
50. Ramaswamy S, Nakamura N, Sansal I, Bergeron L, Sellers WR. 2002. A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell 2: 81-91.
51. Santo EE, Stroeken P, Sluis PV, Koster J, Versteeg R, Westerhout EM. 2013. FOXO3a is a major target of inactivation by PI3K/AKT signaling in aggressive neuroblastoma. Cancer Res 73: 2189-2198.
52. Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJ, Lam EW, Burgering BM, Medema RH. 2002. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol 22: 7842-7852.
53. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, Maecker H, O'Rourke K, Bazan F, Eastham-Anderson J, et al. 2010. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 463: 103-107.
54. Scott BA, Avidan MS, Crowder CM. 2002. Regulation of hypoxic death in C. elegans by the insulin/IGF receptor homolog DAF-2. Science 296: 2388-2391.
55. Semenza GL. 2013. Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene 32: 4057-4063.
56. Seth P, Krop I, Porter D, Polyak K. 2002. Novel estrogen and tamoxifen induced genes identified by SAGE (serial analysis of gene expression). Oncogene 21: 836-843.
57. Sisci D, Maris P, Cesario MG, Anselmo W, Coroniti R, Trombino GE, Romeo F, Ferraro A, Lanzino M, Aquila S, et al. 2013. The estrogen receptor a is the key regulator of the bifunctional role of FoxO3a transcription factor in breast cancer motility and invasiveness. Cell Cycle 12: 3405-3420.
58. Sunayama J, Sato A, Matsuda K, Tachibana K, Watanabe E, Seino S, Suzuki K, Narita Y, Shibui S, Sakurada K, et al. 2011. FoxO3a functions as a key integrator of cellular signals that control glioblastoma stem-like cell differentiation and tumorigenicity. Stem Cells 29: 1327-1337.
59. Sunters A, Fernandez de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA, Coffer PJ, Medema RH, Coombes RC, Lam EW. 2003. FoxO3a transcriptional regulation of Bim controls apoptosis in Paclitaxel-treated breast cancer cell lines. J Biol Chem 278: 49795-49805.
60. Sunters A, Madureira PA, Pomeranz KM, Aubert M, Brosens JJ, Cook SJ, Burgering BM, Coombes RC, Lam EW. 2006. Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Cancer Res 66: 212-220.
61. Takeda K, Ho VC, Takeda H, Duan LJ, Nagy A, Fong GH. 2006. Placental but not heart defects are associated with elevated hypoxia-inducible factor a levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol 26: 8336-8346.
62. Takeda K, Cowan A, Fong GH. 2007. Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation 116: 774-781.
63. Tennant DA, Gottlieb E. 2010. HIF prolyl hydroxylase-3 mediates a-ketoglutarate-induced apoptosis and tumor suppression. J Mol Med 88: 839-849.
64. To KK, Huang LE. 2005. Suppression of hypoxia-inducible factor 1a (HIF-1a) transcriptional activity by the HIF prolyl hydroxylase EGLN1. J Biol Chem 280: 38102-38107.
65. Tothova Z, Gilliland DG. 2007. FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. Cell Stem Cell 1: 140-152.
66. Tsai KL, Sun YJ, Huang CY, Yang JY, Hung MC, Hsiao CD. 2007. Crystal structure of the human FOXO3a-DBD/DNA complex suggests the effects of post-translational modification. Nucleic Acids Res 35: 6984-6994.
67. Tsai WB, Chung YM, Zou Y, Park SH, Xu Z, Nakayama K, Lin SH, Hu MC. 2010. Inhibition of FOXO3 tumor suppressor function by bTrCP1 through ubiquitin-mediated degradation in a tumor mouse model. PLoS ONE 5: e11171.
68. Villen J, Beausoleil SA, Gygi SP. 2008. Evaluation of the utility of neutral-loss-dependent MS3 strategies in large-scale phosphorylation analysis. Proteomics 8: 4444-4452.
69. Witt AE, Hines LM, Collins NL, Hu Y, Gunawardane RN, Moreira D, Raphael J, Jepson D, Koundinya M, Rolfs A, et al. 2006. Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer. J Proteome Res 5: 599-610.
70. Xie L, Xiao K, Whalen EJ, Forrester MT, Freeman RS, Fong G, Gygi SP, Lefkowitz RJ, Stamler JS. 2009. Oxygen-regulated b(2)-adrenergic receptor hydroxylation by EGLN3 and ubiquitylation by pVHL. Sci Signal 2: ra33.
71. Xie Y, Avello M, Schirle M, McWhinnie E, Feng Y, Bric-Furlong E, Wilson C, Nathans R, Zhang J, Kirschner MW, et al. 2013. Deubiquitinase FAM/USP9X interacts with the E3 ubiquitin ligase SMURF1 protein and protects it from ligase activitydependent self-degradation. J Biol Chem 288: 2976-2985.
72. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, et al. 2008. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 10: 138-148.
73. Zhang JH, Qi RC, Chen T, Chung TD, Stern AM, Hollis GF, Copeland RA, Oldenburg KR. 1999. Development of a carbon dioxide-capture assay in microtiter plate for aspartyl-b-hydroxylase. Anal Biochem 271: 137-142.
74. Zhang Q, Gu J, Li L, Liu J, Luo B, Cheung HW, Boehm JS, Ni M, Geisen C, Root DE, et al. 2009. Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell 16: 413-424.